In Brief: SmithKline Beecham/TCPI
This article was originally published in The Gray Sheet
SmithKline Beecham/TCPI: Enter agreement whereby SKB will evaluate for a six-month period Technical Chemicals & Products' TD Glucose Monitoring System, a point-of-care, non-invasive blood glucose monitoring technology. In return, SKB provides TCPI with up-front payments, and agrees to a mutual exchange of technical and marketing information related to the product. SKB has until the end of the six-month period to conduct due diligence, perform market studies and negotiate a definitive worldwide marketing agreement related to the test...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.